UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ COMMISSION FILE NUMBER: 001-38728 AVALON GLOBOCARE CORP. (Exact name of Registrant as specified in its charter) Delaware 47-168512 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ COMMISSION FILE NUMBER: 000-55709 AVALON GLOBOCARE CORP. (Exact name of Registrant as specified in its charter) Delaware 47-1685128 (St ...

Financial Performance - Total revenues for the three months ended March 31, 2020, were $296,956, compared to $284,164 for the same period in 2019, representing a 4% increase[13]. - The net loss attributable to Avalon GloboCare Corp. common shareholders for the three months ended March 31, 2020, was $3,270,781, an improvement from a net loss of $4,405,816 in the same period of 2019, reflecting a 26% reduction in losses[13]. - The company reported a gross profit of $42,455 for the three months ended March 31, 2020, compared to a gross profit of $10,007 for the same period in 2019, marking a significant increase[13]. - Comprehensive loss attributable to Avalon GloboCare Corp. common shareholders for the three months ended March 31, 2020, was $3,292,847, compared to $4,361,136 for the same period in 2019, indicating a reduction of about 25%[13]. - Net loss for the three months ended March 31, 2020, was $3,270,781, a decrease from a net loss of $4,504,929 in the same period of 2019, representing a 27.4% improvement[18]. - Total costs and expenses for the three months ended March 31, 2020, were $254,501, compared to $274,157 in the same period of 2019[108]. Cash Flow and Liquidity - Net cash used in operating activities was $1,998,796 for the three months ended March 31, 2020, compared to $1,422,311 for the same period in 2019, indicating a 40.5% increase in cash outflow[18]. - The cash balance at the end of the period was $635,271, down from $1,769,291 at the end of the same period in 2019, reflecting a decrease of 64.0%[18]. - The current cash balance is insufficient to cover operating expenses for the next twelve months, raising substantial doubt about the Company's ability to continue as a going concern[32]. - The Company plans to raise capital through the sale of equity to implement its business plan, but there are no assurances that these plans will be realized[32]. - The Company maintains cash balances of $635,271 as of March 31, 2020, with $312,818 (49.2%) in the United States and $322,453 (50.8%) in China[44]. - Cash balances held in China include $179,563 that is not covered by insurance, indicating potential risk exposure[42]. Equity and Liabilities - Total equity decreased to $3,710,127 as of March 31, 2020, down from $4,465,073 at the end of 2019, indicating a decline of approximately 17%[12]. - The accumulated deficit increased to $32,632,718 as of March 31, 2020, from $29,361,937 at the end of 2019, representing an increase of about 8%[12]. - Total liabilities and equity as of March 31, 2020, were $10,348,239, slightly down from $10,490,536 at the end of 2019, indicating a decrease of about 1.4%[12]. - Accrued liabilities and other payables increased to $2,650,299 as of March 31, 2020, from $2,570,184 as of December 31, 2019[71]. - The company had $2,900,000 outstanding under the line of credit as of March 31, 2020, compared to $2,600,000 as of December 31, 2019[81]. Research and Development - Research and development expenses for the three months ended March 31, 2020, were $275,402, up from $152,460 in the same period of 2019, indicating an increase of 81%[13]. - The company is focused on advancing immune effector cell therapy and exosome technology, positioning itself as a leader in the CellTech bio-developer space[21]. - The company has formed several subsidiaries to enhance its capabilities in cellular therapies and related consulting services[28]. Acquisitions and Investments - The company acquired Beijing Genexosome for a cash payment of $450,000, with an unpaid acquisition consideration of $100,000 as of March 31, 2020[78]. - The company's equity method investment in Epicon Biotech Co., Ltd. was valued at $466,014 as of March 31, 2020, down from $483,101 as of December 31, 2019[68]. - For the three months ended March 31, 2020, the company's share of Epicon's net loss was $9,084, compared to $12,743 for the same period in 2019[69]. - Avalon Shanghai committed to invest at least RMB 10,000,000 (approximately $1.4 million) in the joint venture Epicon[120]. Legal and Regulatory Matters - The company plans to vigorously defend against legal claims related to misappropriation of trade secrets[111]. Impact of COVID-19 - The COVID-19 pandemic is expected to adversely impact the Company's operations and financial condition for the year 2020, although the financial effect cannot be reasonably estimated at this time[33].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT Commission file number: 000-55709 (Name of registrant as specified in its charter) | --- | --- | |------------------------------------------------------------------------------|------------------------------------------| | D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.0001 par value per share AVCO The NASDAQ Capital Market Class Outstanding November 14, 2019 Common Stock, $0.0001 par value per share 75,771,056 shares FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ COMMISSION FILE NUMBER: 001-38728 AVALON GLOBOCARE CORP. (Exact name of Registrant as specified in its charter) Delaware 47-1685128 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.0001 par value per share AVCO The NASDAQ Capital Market Class Outstanding May 14, 2019 Common Stock, $0.0001 par value per share 75,655,639 shares FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT Commission file number: 000-55709 (Name of registrant as specified in its charter) | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|---------- ...